We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Synthetic MVA-based SARS-CoV-2 Vaccine, COH04S1, for the Prevention of COVID-19 Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04639466
Recruitment Status : Recruiting
First Posted : November 20, 2020
Last Update Posted : January 6, 2022
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
City of Hope Medical Center

Tracking Information
First Submitted Date  ICMJE November 4, 2020
First Posted Date  ICMJE November 20, 2020
Last Update Posted Date January 6, 2022
Actual Study Start Date  ICMJE November 19, 2020
Estimated Primary Completion Date July 31, 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 15, 2021)
  • Incidence of adverse events (Phase I) [ Time Frame: Up to 365 days ]
    Evaluated based on the Division of Microbiology and Infectious Diseases criteria.
  • Incidence of adverse events (Phase II) [ Time Frame: Within the first 7 days following booster injection ]
    Evaluated based on the Division of Microbiology and Infectious Diseases criteria.
  • Antibody levels to SARS CoV-2 Spike protein (Phase II) [ Time Frame: Up to 365 days ]
    Assessed by Ortho VITROS Anti-SARS-CoV-2 IgG Quantitative assay.
  • Fold increase of Spike IgG levels (Phase II) [ Time Frame: At 28 days post-injection ]
Original Primary Outcome Measures  ICMJE
 (submitted: November 19, 2020)
Incidence of adverse events [ Time Frame: Up to 365 days ]
Evaluated based on the Division of Microbiology and Infectious Diseases criteria.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: December 15, 2021)
  • Humoral immunity (Phase I) [ Time Frame: During 1 year of observation ]
    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific IgA, IgG, and IgM measured in serum and saliva by enzyme-linked immunosorbent assay.
  • Level of SARS-CoV-2-specfic neutralizing antibodies (Phase I) [ Time Frame: Up to 365 days ]
    Measure the generation of neutralizing antibodies in participants, and test whether they prevent infection of a susceptible cell line with a pseudo-type of the SARS-CoV-2 virus.
  • Th1 vs Th2 polarization (Phase I) [ Time Frame: Up to 365 days ]
    SARS-CoV-2-specific IFN-gamma, TNF-alpha, IL-2, IL-4, IL6, IL-13 cytokine levels will be measured to assess Th1 vs Th2 polarization.
  • SARS-CoV-2- antigen specific T cell responses to the COH04S1 vaccine (Phase I) [ Time Frame: Up to 365 days ]
    Assessed using overlapping peptide libraries specific for SARS-CoV-2.
  • Evolution of activated/cycling and memory phenotype markers on the surface of SARS-CoV-2- specific T cells elicited as a result of the COH04S1 vaccination (Phase I) [ Time Frame: Up to 365 days ]
  • Comparison of immunogenicity and adverse events (Phase I) [ Time Frame: Up to 365 days ]
    Immunogenicity and adverse events will be compared between one injection versus two injection groups.
  • T lymphocyte production of cytokines in response to in vitro stimulation with overlapping peptide libraries specific for SARS-CoV-2 (Phase II) [ Time Frame: Up to 365 days ]
  • SARS-CoV-2-S and -N specific IFNγ (Th1) and IL-4 (Th2) cytokine levels (Phase II) [ Time Frame: Up to 365 days ]
  • Neutralizing Ab levels (Phase II) [ Time Frame: Up to 365 days ]
    Assessed by ability to prevent infection of a susceptible cell line with Spike pseudo-typed lentivirus representing different SARS-CoV-2 variants.
  • Antibody to SARS CoV-2 Spike protein (Phase II) [ Time Frame: Up to 365 days ]
    Assessed by ORTHO VITROS assay, as well as antibody to N protein, and S protein neutralizing antibodies.
  • T lymphocyte production of cytokines in response to in vitro peptide library stimulation (Phase II) [ Time Frame: Up to 365 days ]
  • COVID-19 disease that is moderate, severe, or critical (Phase II) [ Time Frame: Up to 365 days ]
    Confirmed by polymerase chain reaction (PCR) viral load by Food and Drug Administration (FDA) guidelines February (Feb) 2021.
  • Confirmed COVID-19 infection by PCR viral load (Phase II) [ Time Frame: Up to 365 days ]
  • Moderna or Pfizer vaccine received previously (Phase II) [ Time Frame: Up to 365 days ]
Original Secondary Outcome Measures  ICMJE
 (submitted: November 19, 2020)
  • Humoral immunity [ Time Frame: During 1 year of observation ]
    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific IgA, IgG, and IgM measured in serum and saliva by enzyme-linked immunosorbent assay.
  • Level of SARS-CoV-2-specfic neutralizing antibodies [ Time Frame: Up to 365 days ]
    Level of neutralizing antibodies and percentage of participants with neutralizing antibodies as determined by a pseudotyped lentivirus-S assay.
  • Th1 vs Th2 polarization [ Time Frame: Up to 365 days ]
    SARS-CoV-2-specific IFN-gamma, TNF-alpha, IL-2, IL-4, IL6, IL-13 cytokine levels will be measured to assess Th1 vs Th2 polarization.
  • SARS-CoV-2- antigen specific T cell responses to the COH04S1 vaccine [ Time Frame: Up to 365 days ]
    Percentage of participants with T cell immunity to SARS-CoV-2 S and N proteins post vaccination.
  • Evolution of activated/cycling and memory phenotype markers on the surface of SARS-CoV-2- specific T cells elicited as a result of the COH04S1 vaccination [ Time Frame: Up to 365 days ]
    Percentage of participants with activated/cycling and memory phenotype markers on the surface of SARS-CoV-2- specific T cells elicited as a result of the COH04S1 vaccination
  • Comparison of one vaccine injection vs two vaccine injections for immunogenicity [ Time Frame: Up to 365 days ]
    Immunogenicity will be evaluated based on the percentage of participants with SARS-CoV-2 S and N antibodies and T cell immunity post vaccination.
  • Comparison of one vaccine injection vs two vaccine injections for adverse events [ Time Frame: Up to 365 days ]
    Safety will be evaluated based on the Division of Microbiology and Infectious Diseases criteria.
Current Other Pre-specified Outcome Measures
 (submitted: December 15, 2021)
  • Incidence of coronavirus 2019 (COVID-19) infection (Phase I) [ Time Frame: Up to 365 days ]
    Any incidental COVID-19 infection will be recorded occurring during the study follow-up period. The SARS-CoV-2-specific immune correlates of infected subjects will be compared with those uninfected.
  • Severity of COVID-19 and resolution (Phase I) [ Time Frame: Up to 365 days ]
    Will be summarized descriptively to address concerns related to the potential for vaccine-induced disease enhancement.
  • Incidence of COVID-19 in placebo group (Phase I) [ Time Frame: Up to 365 days ]
    Will be summarized to provide initial data on acquired COVID-19 infections in the same time period and subject pool.
  • SARS-CoV-2-specific neutralizing antibodies (Phase I) [ Time Frame: Up to 365 days ]
  • In depth analysis of Th1 (IFN-gamma, TNF-alpha, IL-2)/Th2 (IL-4, IL-6, IL-13) cytokine expression via intracellular cytokine staining on selected samples (Phase I) [ Time Frame: Up to 365 days ]
  • Phenotype markers on the surface of antigen specific T cells elicited as a result of the COH04S1 vaccination (Phase II) [ Time Frame: Up to 365 days ]
    Will evaluate activated/cycling, cytotoxic/helper, and memory phenotype markers.
  • SARS-CoV-2-specfic IgA and IgG (Phase II) [ Time Frame: Up to 365 days ]
    Measured in serum by enzyme-linked immunosorbent assay (ELISA) during 12 months of observation.
Original Other Pre-specified Outcome Measures
 (submitted: November 19, 2020)
  • Incidence of coronavirus 2019 (COVID-19) infection [ Time Frame: Up to 365 days ]
    Number of participants with incidental COVID-19 infection will be determined during the study follow-up period and correlated with vaccination regimen and placebo.
  • Severity of COVID-19 and resolution [ Time Frame: Up to 365 days ]
    Number of participants with mild versus severe COVID-19 infection will be determined within each vaccine dose level and regimen.
  • Incidence of COVID-19 in placebo group [ Time Frame: Up to 365 days ]
    Number of participants with incidental COVID-19 infection will be determined to provide initial data on acquired COVID-19 infections in the placebo group as an exploratory objective.
 
Descriptive Information
Brief Title  ICMJE A Synthetic MVA-based SARS-CoV-2 Vaccine, COH04S1, for the Prevention of COVID-19 Infection
Official Title  ICMJE Phase 1/2 Dose Escalation Study to Evaluate the Safety and Biologically Effective Dose of COH04S1, a Synthetic MVA-Based SARS-CoV-2 Vaccine, Administered as One or Two Injections or as a Booster to Healthy Adult Volunteers
Brief Summary This phase I trial evaluates the side effects and best dose of COH04S1, a synthetic modified vaccinia Ankara (MVA)-based SARS-CoV-2 vaccine, for the prevention of COVID-19 infection. COVID-19 infection is caused by the SARS-CoV-2 virus. SARS-CoV-2 has demonstrated the capability to spread rapidly, leading to significant impacts on healthcare systems and causing societal disruption. COH04S1 was created by placing small pieces of SARS-CoV-2 DNA (the chemical form of genes) into synthetic MVA, which may be able to induce immunity (the ability to recognize and fight against an infection) to SARS-CoV-2. The purpose of this study is to determine the safety and the optimal dose of the COH04S1 vaccine.
Detailed Description

PRIMARY OBJECTIVE:

I. Safety and tolerability of the synthetic MVA-based SARS-CoV-2 vaccine COH04S1 (COH04S1) vaccine at three different dose levels (DL): 1.0x10^7 plaque-forming unit (PFU)/dose, 1.0x10^8 PFU/dose, and 2.5x10^8 PFU/dose. (Phase I)

II. Evaluate the safety profile of a single-dose vaccine boost at day 7 post-injection of COH04S1. (Phase II)

III. Determine whether the COH04S1 dose levels tested (1.0x107 or 1.0x108) generate promising immune responses (>5-fold increase of Spike IgG over baseline) after single-dose booster injection, and select a promising dose to use for further study. (Phase II)

SECONDARY OBJECTIVES:

I. Longitudinal evaluation of humoral immunity. (Phase I)

II. Quality and properties of cellular and humoral immunity elicited as a result of the vaccination. (Phase I)

III. Explore the role of two injections versus one injection, and evaluate a placebo group. (Phase I)

III. Evaluate T cell-based antigen-specific immune responses at day 28 post-injection of single-dose COH04S1 vaccine boost. (Phase II)

IV. Evaluate SARS-CoV-2 S and N-specific Th1 vs Th2 polarization. (Phase II)

V. Assess levels of SARS-CoV-2 neutralizing antibodies and their activity against variants of concern (VOC) or variants of high consequence (VHC). (Phase II)

VI. Estimate the durability of antibody-based immune responses in a 12-month time period. (Phase II)

VII. Estimate the durability of T-cell-based immune responses in a 12-month time period. (Phase II)

VIII. Estimate the incidence of COVID-19 Moderate and Severe disease during follow-up (12 months). (Phase II)

IX. Evaluate the potential relationship between duration of immunity and COVID infection (incidence) over the 12-month study period. (Phase II)

X. Summarize outcomes, primary and secondary endpoints, based on pre-study mRNA vaccine received. (Phase II)

EXPLORATORY OBJECTIVES:

I. Surveillance for incidental coronavirus disease 2019 (COVID-19) infection during follow-up (1 year). (Phase I)

II. Quality and properties of cellular and humoral immunity elicited as a result of the vaccination. (Phase I)

III. Evaluate activated/cycling, cytotoxic/helper, and memory phenotype markers. (Phase II)

IV. Estimate SARS-CoV-2-specfic serum IgA and IgG over time. (Phase II)

OUTLINE: This is a dose-escalation study.

PHASE I: Participants are randomized to 1 of 3 arms.

ARM I: Participants receive COH04S1 intramuscularly (IM) in the non-dominant upper arm on day 0 and day 28 in the absence of unacceptable toxicity.

ARM II: Participants receive COH04S1 IM in the non-dominant upper arm on day 0 and placebo IM in the non-dominant upper arm on day 28 in the absence of unacceptable toxicity.

ARM III: Participants receive placebo IM in the non-dominant upper arm on day 0 and day 28 in the absence of unacceptable toxicity.

PHASE II: Patients are randomized to 1 of 2 arms.

ARM I: Participants receive low dose COH04S1 booster IM in non-dominant upper arm on day 1 in the absence of unacceptable toxicity.

ARM II: Participants receive high dose COH04S1 booster IM in non-dominant upper arm on day 1 in the absence of unacceptable toxicity.

Participants are followed up at 7, 14, 28, 35, 42, 56, 90, 120, 180, 270, and 365 days.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE COVID-19 Infection
Intervention  ICMJE
  • Drug: Placebo Administration
    Given IM in the non-dominant upper arm
  • Biological: Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
    Given IM in the non-dominant upper arm
    Other Names:
    • COH04S1
    • SARS-CoV-2 Vaccine COH04S1
    • sMVA-based SARS-CoV-2 Vaccine COH04S1
Study Arms  ICMJE
  • Experimental: Phase I Arm I (COH04S1)
    Participants receive COH04S1 IM in the non-dominant upper arm on day 0 and day 28 in the absence of unacceptable toxicity.
    Intervention: Biological: Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
  • Active Comparator: Phase I Arm II (COH04S1, placebo)
    Participants receive COH04S1 IM in the non-dominant upper arm on day 0 and placebo IM in the non-dominant upper arm on day 28 in the absence of unacceptable toxicity.
    Interventions:
    • Drug: Placebo Administration
    • Biological: Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
  • Placebo Comparator: Phase I Arm III (placebo)
    Participants receive placebo IM in the non-dominant upper arm on day 0 and day 28 in the absence of unacceptable toxicity.
    Intervention: Drug: Placebo Administration
  • Experimental: Phase II Arm I (low dose COH04S1 booster)
    Participants receive low dose COH04S1 booster IM in non-dominant upper arm on day 1 in the absence of unacceptable toxicity.
    Intervention: Biological: Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
  • Experimental: Phase II Arm II (high dose COH04S1 booster)
    Participants receive high dose COH04S1 booster IM in non-dominant upper arm on day 1 in the absence of unacceptable toxicity.
    Intervention: Biological: Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: December 15, 2021)
189
Original Estimated Enrollment  ICMJE
 (submitted: November 19, 2020)
129
Estimated Study Completion Date  ICMJE July 31, 2023
Estimated Primary Completion Date July 31, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • PHASE I: Documented informed consent of the participant
  • PHASE I: Age: >= 18 years and < 55 years
  • PHASE I: Ability to read and understand English, Spanish, or Mandarin for consenting
  • PHASE I: Platelets >= 100,000/mm^3 (within 30 days prior to day 0 of protocol therapy unless otherwise stated)
  • PHASE I: White blood cells (WBCs) 3,600-10,100/mm^3 (within 30 days prior to day 0 of protocol therapy unless otherwise stated)
  • PHASE I: Total bilirubin < 1.1 x upper limit of normal (ULN) (within 30 days prior to day 0 of protocol therapy unless otherwise stated)
  • PHASE I: Aspartate aminotransferase (AST) < 1.5 x ULN (within 30 days prior to day 0 of protocol therapy unless otherwise stated)
  • PHASE I: Alanine aminotransferase (ALT) < 1.5 x ULN (within 30 days prior to day 0 of protocol therapy unless otherwise stated)
  • PHASE I: Alkaline phosphatase (AP) < 1.1 x ULN (within 30 days prior to day 0 of protocol therapy unless otherwise stated)
  • PHASE I: Blood urea nitrogen (BUN) < 1.25 x ULN (within 30 days prior to day 0 of protocol therapy unless otherwise stated)
  • PHASE I: Creatinine less than or equal to the ULN (within 30 days prior to day 0 of protocol therapy unless otherwise stated)
  • PHASE I: Sodium 137-145 mEq/L (within 30 days prior to day 0 of protocol therapy unless otherwise stated)
  • PHASE I: Potassium 3.5-5.1 mEq/L (within 30 days prior to day 0 of protocol therapy unless otherwise stated)
  • PHASE I: Carbon dioxide 22-30 mmol/L (within 30 days prior to day 0 of protocol therapy unless otherwise stated)
  • PHASE I: Glucose 80-128 mg/dL (within 30 days prior to day 0 of protocol therapy unless otherwise stated)
  • PHASE I: Albumin 3.5-5.0 g/dL (within 30 days prior to day 0 of protocol therapy unless otherwise stated)
  • PHASE I: Hemoglobin (HGB) > 10.5 gm/dL (within 30 days prior to day 0 of protocol therapy unless otherwise stated)
  • PHASE I: Hematocrit (Hct) (within 30 days prior to day 0 of protocol therapy unless otherwise stated)

    • For females: 34.5-44.6 %
    • For males: 37.6-47.2 %
  • PHASE I: Seronegative for human immunodeficiency virus (HIV) antigen (Ag)/antibody (Ab) combo, hepatitis C virus (HCV), active hepatitis B virus (HBV) (surface antigen negative) (within 30 days prior to day 0 of protocol therapy unless otherwise stated)

    • If positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed
  • PHASE I: History negative for COVID-19 and nasopharyngeal test results pending for SARS-CoV2 performed at City of Hope (COH) on nasal wash samples using the Diasorin Simplexa test (within 30 days prior to day 0 of protocol therapy unless otherwise stated)

    • Baseline SARS-CoV2serologic test will be performed at TGen using the InBios assay; the result will not be required for eligibility
  • PHASE I: A documented electrocardiogram (ECG) and cardiac troponin must be within normal institutional limits in the past 30 days; "normal ECG with sinus tachycardia" or "normal ECG with sinus bradycardia" is allowable based on a history of absent cardiac/exercise related symptoms as determined by the principal investigator (P.I.) in consultation with a senior staff cardiologist (within 30 days prior to day 0 of protocol therapy unless otherwise stated)
  • PHASE I: Women of childbearing potential (WOCBP): negative urine or serum pregnancy test (within 30 days prior to day 0 of protocol therapy unless otherwise stated)

    • If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
  • PHASE I: Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 weeks after the last dose of protocol therapy

    • Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)
  • PHASE II: Prior COVID-19 mRNA vaccination with EUA or FDA-approved vaccine, >= 6 months prior
  • PHASE II: ECOG performance score 0-1
  • PHASE II: Documented informed consent of the participant
  • PHASE II: Age: >= 18 years
  • PHASE II: Ability to read and understand English, Spanish, or Mandarin for consenting
  • PHASE II: Platelets >= 100,000/mm^3 (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)
  • PHASE II: WBCs 3,600-10,100/mm^3 (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)
  • PHASE II: Total bilirubin < 1.1 X ULN (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)
  • PHASE II: AST < 1.5 x ULN (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)
  • PHASE II: ALT < 1.5 x ULN (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)
  • PHASE II: AP < 1.1 x ULN (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)
  • PHASE II: BUN < 1.25 x ULN (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)
  • PHASE II: Creatinine less than or equal to the ULN (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)
  • PHASE II: Sodium 137-145 mEq/L (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)
  • PHASE II: Potassium 3.5-5.1 mEq/L (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)
  • PHASE II: Carbon dioxide 22-30 mmol/L (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)
  • PHASE II: Glucose 80-128 mg/dL (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)
  • PHASE II: Albumin 3.5-5.0 g/dL (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)
  • PHASE II: HGB > 10.5 gm/dL (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)
  • PHASE II: Hematocrit (Hct) (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)

    • For females: 34.5-44.6 %
    • For males: 37.6-47.2 %
  • PHASE II: Seronegative for HIV Ag/Ab combo, HCV, active HBV (Surface Antigen Negative) (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)

    • If positive, hepatitis C RNA quantitation must be performed
  • PHASE II: Women of childbearing potential (WOCBP): negative urine or serum pregnancy test (performed within 30 days prior to day 0 of protocol therapy unless otherwise stated)

    • If the urine pregnancy test is inconclusive a serum pregnancy test will be required
  • PHASE II: Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 weeks after the booster

    • Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)

Exclusion Criteria:

  • PHASE I: Participants at increased risk of exposure to SARS-CoV-2, such as patient-facing health care workers and emergency responders are excluded
  • PHASE I: Participants who would be at higher risk for severe COVID-19 according to known risk factors are excluded e.g. type 2 diabetes, obesity (body mass index [BMI] >= 35), congestive heart failure (New York Heart Association class >= I), history of coronary artery disease, or chronic obstructive pulmonary disease
  • PHASE I: Participants using investigational or licensed agents that may prevent or treat SARS-CoV-2 are excluded
  • PHASE I: Participants are excluded, who have any history of allergic diatheses as defined by a history of asthma, anaphylaxis, or generalized urticaria, or by daily use of antihistamines, episodic (more than once in past 3 months) inhalational medications including steroidal agents, non-steroidal agents, or cromolyn sodium
  • PHASE I: Any previous condition, or one that becomes known during the screening period, which would suggest that the technicians and health professionals involved in the study would be exposed to specific infectious risk
  • PHASE I: Surgery in past 6 months that required general anesthesia. Minor procedures, such as dental surgery and superficial diagnostic biopsies, are permitted
  • PHASE I: Taking daily medications for chronic or intercurrent illness. Medications excluded from this rule are: thyroid replacement, estrogen replacement, dietary vitamins and protein supplements, mild anti-depressant and anxiety medication, and any medication not known or likely to be immunosuppressive, as determined by the P.I.
  • PHASE I: Participants who have had a live vaccine =< 30 days prior to administration of study vaccine or subjects who are =< 2 weeks within administration of inactivated vaccines (e.g. influenza vaccine). Flu shots are allowed > 2 weeks before the first injection and > 2 weeks post 2nd injection
  • PHASE I: Treatment with medication for high cholesterol or other lipid abnormality. Prophylactic medication is acceptable
  • PHASE I: History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent
  • PHASE I: History of adverse event with a prior smallpox vaccination
  • PHASE I: Any previous condition, or one that becomes known during the screening period, that would suggest that the individual could be immunologically impaired, or for which this study would pose a danger to him/herself or about which the P.I., in evaluating the subject for eligibility, determines that this exclusion is appropriate
  • PHASE I: Participants are excluded who have history of cancer other than basal cell skin cancer, or any condition, psychiatric or otherwise, that would preclude informed consent, consistent follow-up or compliance with any aspect of the study (e.g., untreated schizophrenia or other significant cognitive impairment, etc. as determined by the P.I.)
  • PHASE I: Participants with severe migraine headaches (more than one per month on average in the past 6 months or requiring preventive medication) are excluded but those on effective medication (less than one migraine per month) are allowed to enroll
  • PHASE I: History of heart disease, e.g. previous treated arrhythmia or myocardial infarction
  • PHASE I: Horizontal positioning- induced or activities of normal living exercise-induced shortness of breath
  • PHASE I: History of stroke or claudication
  • PHASE I: Any of the following cardiac findings of ECG abnormality: 1) conduction disturbance (complete left or right bundle branch block, intraventricular conduction disturbance with QRS > 120 ms, atrioventricular block [AV] block of any degree, and corrected QT [QTc] prolongation > 450 msec for men and > 460 msec for women); 2) repolarization (ST segment or T wave) abnormality; 3) significant atrial or ventricular arrhythmia, including frequent ectopy (e.g., 2 premature ventricular contractions in a row); and 4) evidence of past myocardial infarction.
  • PHASE I: Poxvirus vaccine in the last 12 months
  • PHASE I: Any MVA vaccine or poxvirus vaccine in the last 12 months
  • PHASE I: Any previous SARS-CoV-2 vaccine
  • PHASE I: History of or prior treatment for diabetes type 1 or diabetes type 2; BMI < 18 or > 35. BMI can be rounded to the nearest integer
  • PHASE I: Clinically significant uncontrolled illness
  • PHASE I: Active infection requiring treatment
  • PHASE I: Known history of immunodeficiency virus (HIV) or hepatitis B or hepatitis C infection
  • PHASE I: Diagnosis which has been associated with immunodeficiency
  • PHASE I: Females only: Pregnant or breastfeeding
  • PHASE I: Men with partners of child-bearing potential and women of children-bearing potential who are not willing to use medically effective birth control methods, e.g. contraceptive pill, condom, or diaphragm, and continue this for 6 weeks after the second and last dose of vaccine
  • PHASE I: Participants who are employed by or are a student at City of Hope and are in a chain of command that reports directly to persons listed on the protocol as principal investigator or co-investigators; or are relatives or partners of the investigators
  • PHASE I: Any other condition that would, in the investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns with clinical study procedures
  • PHASE I: Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
  • PHASE I: Anyone considered to be in a vulnerable population as defined in 45 CFR 46.111 (a)(3) and 45 CFR 46, Subparts B-D
  • PHASE II: Participants who would be at higher risk for severe COVID-19 according to known risk factors are excluded e.g. type 2 diabetes, obesity (BMI > 35), congestive heart failure (New York Heart Association Class >= I), history of coronary artery disease, cardiomyopathies, sickle cell disease, smoking, chronic kidney disease, immunocompromised state from solid organ transplant, or chronic obstructive pulmonary disease
  • PHASE II: Participants are excluded, who have any history of allergic diatheses as defined by a history of asthma, anaphylaxis, or generalized urticaria, episodic (more than once in past 3 months) inhalational medications including steroidal agents, non-steroidal agents, or cromolyn sodium
  • PHASE II: Any previous condition, or one that becomes known during the screening period, which would suggest that the technicians and health professionals involved in the study would be exposed to specific infectious risk
  • PHASE II: Taking daily medications for chronic or intercurrent illness. Medications excluded from this rule are: thyroid replacement, estrogen replacement, dietary vitamins and protein supplements, mild anti-depressant and anxiety medication, and any medication not known or likely to be immunosuppressive, as determined by the P.I.
  • PHASE II: Participants who have had a live vaccine =< 30 days prior to administration of study vaccine or participants who are =< 2 weeks within administration of inactivated vaccines (e.g. influenza vaccine). Flu shots are allowed > 2 weeks before the booster injection and > 2 weeks post booster injection
  • PHASE II: Intensive cytotoxic therapies, B- or T-cell depleting therapies, or checkpoint inhibitors within 30 days of enrollment
  • PHASE II: Systemic corticosteroids required for chronic conditions at doses > 0.5 mg/kg/day prednisone equivalent within 14 days of enrollment
  • PHASE II: Previously received a COVID-19 vaccine booster injection
  • PHASE II: History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent
  • PHASE II: History of adverse event with a prior smallpox vaccination
  • PHASE II: Any prev
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 55 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04639466
Other Study ID Numbers  ICMJE 20447
NCI-2020-08335 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
20447 ( Other Identifier: City of Hope Medical Center )
P30CA033572 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party City of Hope Medical Center
Original Responsible Party Same as current
Current Study Sponsor  ICMJE City of Hope Medical Center
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE National Cancer Institute (NCI)
Investigators  ICMJE
Principal Investigator: Randy A Taplitz City of Hope Comprehensive Cancer Center
PRS Account City of Hope Medical Center
Verification Date December 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP